Results 181 to 190 of about 2,092,286 (303)

Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series. [PDF]

Ann Hematol, 2023
Hu M, Liu R, Li J, Zhang L, Cao J, Yue M, Zhong D, Tang R.   +7 more
europepmc   +1 more source

Transcriptome-based immune subtypes reveal the heterogeneity of tumor microenvironment in pediatric B-cell acute lymphocytic leukemia. [PDF]

Front Oncol
Meng H, Li X, Hou W, Li J, Fu Y.
europepmc   +1 more source

Microbial and host factors contribute to bloodstream infection in a pediatric acute lymphocytic leukemia mouse model. [PDF]

Heliyon, 2022
Song Y, Perlman K, Gyarmati P.
europepmc   +1 more source

Impact of DNA Ligase 1 Genotypes on Childhood Acute Lymphocytic Leukemia. [PDF]

In Vivo
Hsu PC, Chen CC, Tsai HW, Chang WS, Pei JS, Wang YC, Lin ML, He JL, Chen SS, Tsai CW, Bau DT.   +10 more
europepmc   +1 more source

Extramedullary Involvement of the Ascending Colon in Relapsing Acute Lymphocytic Leukemia: A Case Report. [PDF]

Saudi J Med Med Sci, 2022
Ifthikar Z, Muthalib HA, Mohammed S, Alfraih FA, Aljohany HA, Alsohaibani FI.   +5 more
europepmc   +1 more source

Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study. [PDF]

Blood Cancer J
Ju L, Gao S, Zhang J, Liu Y, Song Q, Dong L, Guo Y, Qin X, Zou J, Yuan C, Shi Y, Kong D, Wang K, Li Q, Yang D, Teng Q, Jiang E, Peng J, Bai G.   +18 more
europepmc   +1 more source

Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study. [PDF]

BMC Cancer, 2022
Qiu KY, Zhou DH, Liao XY, Huang K, Li Y, Xu HG, Weng WJ, Xu LH, Fang JP.   +8 more
europepmc   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

1,5-Anhydroglucitol promotes pre-B acute lymphocytic leukemia progression by driving glycolysis and reactive oxygen species formation. [PDF]

BMC Cancer, 2023
Zhu H, Ma H, Dong N, Wu M, Li D, Liu L, Shi Q, Ju X.   +7 more
europepmc   +1 more source

Disparities in Acute Lymphocytic Leukemia Outcomes Among Young Adults. [PDF]

J Hematol
McKinnell Z, Tuerff D, Hammudi M, Hamilton C, Antonio M, Subrahmanyam R, Ascensao J, Jain MR.   +7 more
europepmc   +1 more source